Table 1 Patients referred for “refractory CIDP” who met “definite” CIDP criteria but had alternate diagnosis
POEMS | CANOMAD | Neurolymphomatosis | |
|---|---|---|---|
Number of patients, N | 5 | 1 | 1 |
Age, median (range) | 52 (33–66) | 61 | 77 |
Sex | |||
M | 4 | 1 | 0 |
F | 1 | 0 | 1 |
Onset | |||
Acute | 1 | 0 | 0 |
Subacute | 3 | 0 | 1 |
Insidious | 1 | 1 | 0 |
Weakness | |||
Uppers | 5 | 1 | 1 |
Lowers | 5 | 1 | 1 |
Diminished sensation | |||
Uppers | 4 | 1 | 1 |
Lowers | 4 | 1 | 1 |
Pain | 4 | 1 | 1 |
Ataxia | 0 | 1 | 0 |
Tremor | 0 | 1 | 0 |
Ophthalmoplegia | 0 | 1 | 0 |
Edema | 5 | 0 | 1 |
Autonomic dysfunction | 2 | 0 | 0 |
Diabetes | 0 | 0 | 0 |
Weight loss | 3 | 0 | 1 |
Early onset atrophy | 2 | 0 | 0 |
Skin changes | 4 | 0 | 0 |
Sclerotic bony lesions | 3 | 0 | 0 |
CSF cyto-albuminologic dissociation, N (range) | 3 (90–144) | 1 (84) | 0 (34) |
Monoclonal protein, N | |||
Lamda | 5 | 0 | 1 |
Kappa | 0 | 1 | 0 |
VEGF elevation, N (range) | 4 (151–771) | N/A | 0 |
ANA positivity, N (ratio) | 1 (1:320) | N/A | 0 |
TLI | |||
Median (wrist-elbow) | 0.67 (0.58–0.79) | 0.47 | 0.52 |
Ulnar (wrist-below elbow) | 0.67 (0.57–0.76) | 0.48 | 0.59 |